Teva Enters Up-to-$376M Deal for Xenon Pain Drug | Pharmaceutics_R&D |
Generic drug giant seeks to expand branded portfolio of pain, CNS drugs.

Teva. Pharmaceutical Industries will develop and market Xenon Pharmaceuticals’ clinical-stage pain treatment XEN402 worldwide, as the generic drug giant seeks to expand its branded portfolio of drugs for pain and CNS indications. (...) - Genetic Engineering & Biotechnology News, Dec 11, 2012